Hongbo Wu1, Ting Huang2, Zhifeng Ye2, Xiaoqing Fu2, Keke Hu2, Xuefei Yang3. 1. Department of Emergency Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. 2. Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine, Guangxing Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, China. 3. Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine, Guangxing Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, China. Electronic address: yang_2019_xf@sina.com.
Abstract
PURPOSE: To explore the correlation of MIR17HG polymorphism with susceptibility and prognosis of multiple myeloma (MM). PATIENTS AND METHODS: A total of 217 MM patients treated with high-dose melphalan combined with autologous peripheral blood stem-cell transplantation at our hospital were enrolled as the case group, and 220 healthy people were included as the control group. Sequenom MassARRAY iPLEX Gold single nucleotide polymorphism genotyping was used to detect polymorphisms of MIR17HG, including rs7336610, rs17735387, rs4284505, and rs1428. RESULTS: An increased risk of MM was found in patients who carried the rs7336610 T allele and rs4284505 G allele, and the higher the Durie-Salmon and International Staging System stages were, the more MM patients carrying rs7336610 CT + TT genotype and rs4284505 AG + GG genotype (all P < .05). Haplotype AC (rs4284505-rs1428) and CA (rs7336610-rs4284505) evidently reduce MM risk, whereas haplotype GC (rs4284505-rs1428) significantly elevated MM risk (all P < .05). Kaplan-Meier curve analysis demonstrated that rs7336610 CC genotype carriers had higher 5-year survival rate than CT + TT genotype carriers (P = .034), and the AA genotype carriers of rs4284505 had higher 5-year survival rate than AG + GG genotype carriers (P < .001). CONCLUSION: Polymorphisms of MIR17HG rs7336610 and rs1428 were correlated with MM risk and prognosis.
PURPOSE: To explore the correlation of MIR17HG polymorphism with susceptibility and prognosis of multiple myeloma (MM). PATIENTS AND METHODS: A total of 217 MM patients treated with high-dose melphalan combined with autologous peripheral blood stem-cell transplantation at our hospital were enrolled as the case group, and 220 healthy people were included as the control group. Sequenom MassARRAY iPLEX Gold single nucleotide polymorphism genotyping was used to detect polymorphisms of MIR17HG, including rs7336610, rs17735387, rs4284505, and rs1428. RESULTS: An increased risk of MM was found in patients who carried the rs7336610 T allele and rs4284505 G allele, and the higher the Durie-Salmon and International Staging System stages were, the more MM patients carrying rs7336610 CT + TT genotype and rs4284505 AG + GG genotype (all P < .05). Haplotype AC (rs4284505-rs1428) and CA (rs7336610-rs4284505) evidently reduce MM risk, whereas haplotype GC (rs4284505-rs1428) significantly elevated MM risk (all P < .05). Kaplan-Meier curve analysis demonstrated that rs7336610 CC genotype carriers had higher 5-year survival rate than CT + TT genotype carriers (P = .034), and the AA genotype carriers of rs4284505 had higher 5-year survival rate than AG + GG genotype carriers (P < .001). CONCLUSION: Polymorphisms of MIR17HGrs7336610 and rs1428 were correlated with MM risk and prognosis.